November 3rd, 2009

Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients with Shift Work Disorder

By Kelley Luckstein

Cephalon, Inc. (Nasdaq: CEPH) today announced that the  November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD). NUVIGIL, the longer-lasting isomer of modafinil, is indicated to improve wakefulness in patients with excessive sleepiness associated with shift work disorder, treated obstructive sleep apnea and narcolepsy. These data were part of the new drug application approved by the FDA in 2007.

 

Reuters, 11/2/09

Tags: Mayo Clinic Proceedings, Mayo Clinic Proceedings, NUVIGIL

Contact Us · Privacy Policy